PuriActives® 生物智造视黄醛

Active ingredient science / 2026

PuriActives® BioRetinal

BioRetinal / INCI: RETINAL

Biotechnologically produced retinaldehyde: one metabolic step from retinoic acid

Retinaldehyde

C₂₀H₂₈O · 284.4 g/mol; the direct precursor of retinoic acid

Scientific and technical product information: skin, scalp, and formulation

Chemical structure source: PubChem CID 638015

PuriPharm Co. Ltd.

Product positioning

A defined retinoid identity for formulation innovation

PuriActives® BioRetinal combines biotechnological production with published research on topical retinaldehyde.

01

Product identity

PuriActives® BioRetinal

One enzymatic step to retinoic acid

INCI: Retinal · C₂₀H₂₈O · 284.4 g/mol

Retinaldehyde is immediately upstream of retinoic acid in cutaneous vitamin A metabolism, with a defined retinoid identity and direct topical research.

[16] PubChem, Retinal CID 638015 · [1] Zasada & Budzisz, 2019

PuriPharm Co. Ltd.

Evidence framework

One molecule connects complementary lines of research

Direct retinaldehyde studies underpin the skin care evidence; related studies inform delivery and follicle biology.

Direct retinaldehyde evidence

Topical retinaldehyde studies

Human studies assess wrinkles, texture, hydration, pigmentation, and tolerability. In vitro and human microbiology studies also inform blemish-prone skin care.

Related research

Mechanistic and application research

RA/tretinoin studies help explain follicular responses; PRN and RSC studies explore stabilization and delivery.

Human studies: 0.05% and 0.1% topical formulas. In vitro studies: Propionibacterium acnes susceptibility. Delivery studies: niosomes and proretinal systems.

Every result applies to its tested retinoid, carrier, model, and regimen.

[3] Mukherjee et al., 2006 · [12] Everts, 2012

PuriPharm Co. Ltd.

Scientific basis

Retinaldehyde is one enzymatic step from an active retinoid ligand

Cutaneous metabolism connects precursor identity with RAR/RXR-mediated gene transcription.

Preclinical validation

Topical 0.05% retinaldehyde increased tissue RA in mouse tail skin and produced retinoid biological responses. [2]

This metabolic position distinguishes retinaldehyde from retinol and retinoic acid. It does not justify exchanging efficacy conclusions or claiming a marketing potency multiplier.

[1] Zasada & Budzisz, 2019 · [2] Didierjean et al., 1996

PuriPharm Co. Ltd.

Scientific basis

From nuclear signaling to measurable skin outcomes

Mechanistic research provides biological context; human studies assess efficacy.

Mechanistic context

RAR / RXR activation

↓

Keratinocyte differentiation and epidermal renewal

↓

Extracellular matrix homeostasis

Mechanistic value requires validation in a defined formula using appropriate measurements.

[1] Zasada & Budzisz, 2019 · [3] Mukherjee et al., 2006

PuriPharm Co. Ltd.

Skin evidence

Topical retinaldehyde research spans more than two decades

Different study designs and formulas provide multidimensional evidence for skin care development.

1998

0.05% RAL, RA, and vehicle comparison

Profilometric assessment of wrinkles and roughness; follow-up to 44 weeks [4]

1999

0.05% RAL, 2 weeks

Significant reduction in viable P. acnes [5]

2018

40 women, 3 months

Texture, TEWL, hydration, and melanin index [6]

2024

32 women, 8 weeks

0.1% retinaldehyde combination serum, 3 nights per week [8]

2025

27 participants, 6 weeks

Anhydrous 0.1% retinaldehyde combination concentrate [9]

2026

56 women, 24 weeks

Blinded split-face study of two RAL formulas [10]

[4] Creidi 1998 · [6] Kwon 2018 · [9] Åkerström 2025 · [10] Deda 2026

PuriPharm Co. Ltd.

Skin evidence / Wrinkles

Different retinaldehyde formulas show visible wrinkle improvement

Instrumental studies link short-term imaging with longer-term wrinkle profiling.

−14%

Fine-line improvement at week 6

Cohort median; p<0.0001 [9]

12-week split-face study

Length −71.1%; area −79.9%; volume −81.25%

Median changes on the left forehead treated with the 0.1% RAL formula; respective p values: 0.018, 0.009, and 0.008. Different combination formulas were used on the two sides. [10]

Representative forehead region at baseline and week 6, with corresponding 3D analysis. Original Figure 9; anhydrous 0.1% retinaldehyde combination formula. [9]

The image shows a representative region; its change is not the cohort median.

[9] Åkerström et al., 2025, Figs 2 & 9 · [10] Deda et al., 2026

PuriPharm Co. Ltd.

Skin evidence / Firmness

Biomechanical and ultrasound measures expand the aging-skin evidence

In a split-face retinaldehyde study, Cutometer R2 increased in multiple facial regions after 24 weeks.

24 weeks

R2 / Overall elasticity

R2 increased significantly in forehead, cheek, and chin regions after 24 weeks (N=52).

High-frequency ultrasound also showed increased dermal density in the assessed regions.

Original Figure 12. T0 = baseline, T1 = week 24; different retinaldehyde combination formulas were used on the two sides. [10]

[10] Deda et al., 2026, Fig 12

Figure key: point = median; box = interquartile range; whiskers = minimum–maximum; R/L = right/left.

PuriPharm Co. Ltd.

Skin evidence / Texture and barrier

Both study concentrations improve texture, hydration, and TEWL

A randomized double-blind study compared 0.1% and 0.05% retinaldehyde creams over three months.

Change from baseline after 3 months (%)

Measure
0.1% RAL
0.05% RAL
Texture improvement
13.7%
12.6%
TEWL reduction
14.5%
17.9%
Hydration increase
10.2%
6.0%

Data from Kwon et al. [6]. Overall photoaging improvement was reported in 95% of both groups. There was no vehicle group, and between-concentration differences in the measures above were not significant.

+12%

Texture improvement at week 6 in a separate study of an anhydrous 0.1% retinaldehyde combination formula [9]

[6] Kwon et al., 2018 · [9] Åkerström et al., 2025, Fig 4

PuriPharm Co. Ltd.

Skin evidence / Skin tone

Retinaldehyde formulas show measurable pigmentation improvement

Melanin index and imaging findings are complementary across three independent clinical studies.

−12%

Pigmentation improvement at week 6

Cohort median; p<0.0001 [9]

19%

Improvement in visible pigmentation

0.1% retinaldehyde + peptides/ceramides/lipids; 8 weeks [8]

6.5%

Melanin index improvement after 3 months in the 0.1% RAL group [6]

Representative pigmentation analysis at baseline and week 6. Original Figure 11; anhydrous 0.1% retinaldehyde combination formula. [9]

The image shows a representative regional change, presented separately from the cohort median.

[6] Kwon 2018 · [8] Konisky 2024 · [9] Åkerström 2025, Fig 11

PuriPharm Co. Ltd.

Skin evidence / Blemish-prone skin

Antibacterial and comedonal-care findings broaden potential applications

Direct P. acnes susceptibility testing complements a four-week study of retinaldehyde-loaded niosomes.

Minimum inhibitory concentration

P. acnes strain
RAL MIC
RA MIC
CIP179
4 mg/L
>128 mg/L
CIP53119
4 mg/L
>128 mg/L
CIP53117
8 mg/L
>128 mg/L

Daily 0.05% retinaldehyde significantly reduced viable P. acnes after 2 weeks; the vehicle did not. MIC is a microbiological measure, not a formulation use level. [5]

Sebum level (μg/cm²)

Time
Sebum (μg/cm²)
Baseline
327.95
Week 2
282.6
Week 4
250.65

0.05% retinaldehyde-loaded niosomal nanoemulsion, used daily for 4 weeks; n=23; p<0.05. Findings apply to the niosomal system studied. [7]

[5] Pechère et al., 1999 · [7] Kim et al., 2021

PuriPharm Co. Ltd.

Skin evidence / Tolerability

Favorable tolerability supports regular, sustained use

Evidence includes a 44-week controlled trial, recent clinical formulas, and instrumental erythema assessment.

44 weeks

0.05% retinaldehyde was well tolerated; retinoic acid caused more local irritation and affected adherence. [4]

1 / 56

One participant reported skin irritation in the 24-week split-face retinaldehyde study. [10]

Patch testing

The tested 0.1% retinaldehyde combination serum showed no evidence of irritation or sensitization. [8]

p = 0.6664

Objective erythema did not change significantly at week 6 in the anhydrous 0.1% retinaldehyde study; mild adverse events were reported. [9]

Tolerability remains formula- and regimen-dependent. Several recent studies gradually increased application frequency.

[4] Creidi 1998 · [8] Konisky 2024 · [9] Åkerström 2025 · [10] Deda 2026

PuriPharm Co. Ltd.

Formulation science / Stability

The polyene structure makes stabilization a formulation priority

Covalent proretinal research quantifies the effects of light, oxygen, and carrier design.

40°C + sunlight + air

1 vs 0.2

Relative degradation rate during the first hour: free retinaldehyde versus proretinal nanoparticles (PRN).

8 months / 25°C / protected from light

Free retinaldehyde: >90% degradation

PRN: <10% retinoid loss

Original Figure 3. PRN is a research chitosan–retinaldehyde system. Free retinaldehyde was solubilized in ethanol. These findings are not BioRetinal stability specifications. [11]

[11] Pisetpackdeekul et al., 2016, Fig 3

Original axes: relative retinal amount (%) and time (minutes); PRN = proretinal nanoparticles.

PuriPharm Co. Ltd.

Formulation science / Delivery

Controlled release connects stability with skin performance

PRN illustrates sustained release from a covalent carrier at skin-relevant pH and changes in topical outcomes.

Release into artificial sebum

Original Figure 4. PRN was tested in artificial sebum at pH 5.0 and 4°C, protected from light, with sustained release measured for 8 hours. [11]

12-week split-face comparison

Original Figure 7. PRN hydrogel versus 0.025% RA hydrogel, twice daily; n=30. Surface parameter −12.5% versus −7.1%; volume parameter −9.2% versus −5.1%. [11]

[11] Pisetpackdeekul et al., 2016, Figs 4 & 7

Figure labels include retinal released (%), time (hours), surface/volume, and texture parameters: energy, entropy, homogeneity, contrast, and variance.

PuriPharm Co. Ltd.

Formulation science / Development

Design around retention, compatibility, and delivery

The goal is to maintain retinaldehyde stability during manufacturing, storage, and consumer use.

01 · Carrier architecture

Assess solubilization, aqueous exposure, and retinaldehyde distribution in the intended format.

02 · Light and oxygen control

Assess formula and packaging exposure during processing, filling, and daily use.

03 · Compatibility and processing

Screen antioxidants, chelators, polymers, and other excipients in the actual system.

04 · Finished-formula validation

Track retinaldehyde content, degradation profile, appearance, and performance over time.

Evidence to establish

Retinaldehyde content; degradation products; packaging compatibility; microbiological quality; scalp/skin tolerability; application performance.

Potential formats: night serums, creams, and leave-on scalp concepts.

[9] Åkerström et al., 2025 · [11] Pisetpackdeekul et al., 2016

PuriPharm Co. Ltd.

Chapter 02 / Scalp and follicle science

A biologically grounded direction for scalp innovation

Retinoid metabolism participates in follicle biology. The opportunity requires rigorous translation, rather than borrowing hair-growth claims from other retinoids.

Follicular structure across the hair cycle. Original Figure 2, Everts 2012. [12]

Current evidence has not established hair-growth efficacy for BioRetinal.

Hair-cycle labels: telogen, anagen, and catagen. Anatomical labels include sebaceous gland, bulge, hair fiber, inner root sheath (cuticle, Huxley’s and Henle’s layers), companion layer, outer root sheath, connective tissue sheath, secondary germ, dermal papilla, matrix, and bulb.

PuriPharm Co. Ltd.

Scalp and follicle science

The pilosebaceous unit has its own retinoid metabolism

Retinaldehyde lies between retinol and RA in follicular signaling.

Local metabolic sequence

Retinol → Retinaldehyde → RA

DHRS9 ALDH1A1 / 2 / 3

Regulated in space and time

RA-synthesizing enzymes, binding proteins, and receptors are distributed in follicular stem-cell-associated regions, with expression patterns changing across the hair cycle.

The biological goal is homeostasis, rather than maximum retinoid exposure.

Original Figure 3. Components associated with follicular RA synthesis and reporter activity. [12]

[12] Everts, 2012, Fig 3

PuriPharm Co. Ltd.

Scalp and follicle science / Related retinoids

RA/tretinoin research informs hypotheses for follicle biology

Test compound: retinoic acid/tretinoin. These results do not demonstrate retinaldehyde efficacy.

Original Figure 3. Human AGA follicle organ culture: RA concentration series, morphology, hair-cycle stage, and proliferation measures. [13]

Original Figure 6. 0.025% tretinoin versus 5% minoxidil, twice daily; 30 participants per group. [13]

[13] Wen et al., 2025, Figs 3 & 6

PuriPharm Co. Ltd.

Scalp and follicle science / Dose response

Follicular responses depend on dose, model, and retinoid

Different RA study findings support direct retinaldehyde research rather than efficacy extrapolation.

AGA follicle organ culture

10⁻¹² M RA

≈1.3× anagen proportion

In Wen’s study, hair-shaft elongation increased and anagen morphology was maintained versus DMSO. [13]

Human anagen VI scalp follicles

10⁻⁸ / 10⁻¹⁰ M ATRA

Approximately 80% catagen-like

In Foitzik’s study, approximately 30% of controls were catagen-like on day 6, and TGF-β2 was upregulated with ATRA treatment. [14]

Next evidence step: directly assess retinaldehyde scalp tolerability, exposure, and follicular responses under defined formulation conditions.

[13] Wen et al., 2025 · [14] Foitzik et al., 2005

PuriPharm Co. Ltd.

Scalp and follicle science / Delivery research

Follicular targeting provides a specific formulation research model

An ex vivo porcine ear study tracked retinaldehyde release from a succinyl chitosan particle system.

01 / Particle design

RSC, 200–300 nm + vitamin E

Retinaldehyde was covalently linked to succinyl chitosan, combining an imine bond, a matrix, and antioxidant protection. [15]

02 / Ex vivo skin

Porcine ear skin; follicular penetration; confocal fluorescence imaging.

03 / Retinaldehyde release

Release into skin tissue

The technical abstract reports that labeled particles entered follicles, followed by retinaldehyde release. [15]

Ex vivo delivery evidence only; it does not demonstrate hair growth in humans.

[15] Supmuang & Wanichwecharungruang, TechConnect 2012

PuriPharm Co. Ltd.

Application development

Skin care concepts focused on measurable outcomes

Each concept links consumer goals with formulation and evidence priorities.

01 · Night-time renewal

Fine lines, firmness, and long-term skin quality

Retinaldehyde retention; gradual-use regimen; imaging and Cutometer assessment.

Serum or cream

02 · Texture and skin tone

Smoothness, hydration, and visible pigmentation

Barrier support; compatibility; Antera/melanin index assessment.

Targeted leave-on care

03 · Blemish-prone skin care

Comedonal appearance and excess surface oil

Delivery selection; sebum and lesion counts; tolerability.

Lightweight leave-on formula

Development principle: validate the complete formula and regimen, beyond ingredient identity.

[5] Pechère 1999 · [6] Kwon 2018 · [9] Åkerström 2025 · [10] Deda 2026

PuriPharm Co. Ltd.

Application development / Scalp

Translate follicle biology into a rigorous scalp development plan

A leave-on scalp serum is a research concept requiring defined formulation, tolerability, and efficacy milestones.

Concept / Leave-on scalp serum

A lightweight, targeted scalp care format

Design for retinaldehyde retention, scalp comfort, and controlled deposition. Treat follicular delivery as a research variable rather than an established product feature.

Development stages

01 Formulation

Retinaldehyde content, degradation profile, packaging compatibility, and deposition.

02 Tolerability

Scalp redness, itching, dryness, and participant comfort.

03 Exploratory efficacy

Phototrichogram assessment: hair count, density, diameter, and anagen proportion.

04 Translational validation

Define the comparator, regimen, and duration before developing claims.

Initial goal: a stable, well-tolerated scalp formula for controlled efficacy research.

[12] Everts 2012 · [13] Wen 2025 · [15] Supmuang 2012

PuriPharm Co. Ltd.

Core value

BioRetinal connects ingredient identity with evidence-based development

Core value for international skin care and scalp innovation teams.

01 · Biotechnological production

A defined product feature without unsupported process or certification claims.

02 · Direct precursor of RA

Immediately upstream of retinoic acid, requiring one enzymatic conversion.

03 · Extensive skin research

Human studies address wrinkles, texture, skin tone, blemish-prone skin care, and tolerability.

04 · A rigorous innovation pathway

Formulation-first development, with scalp research grounded in follicle biology.

[1] Zasada & Budzisz 2019 · [6] Kwon 2018 · [10] Deda 2026 · [12] Everts 2012

PuriPharm Co. Ltd.

References

References / Mechanisms and skin evidence

Reference numbers match the in-text citations. Original figure numbers and study conditions appear in the adjacent captions.

[1] Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Adv Dermatol Allergol. 2019;36:392–397. DOI: 10.5114/ada.2019.87443.

[2] Didierjean L, Carraux P, Grand D, et al. Topical retinaldehyde increases skin content of retinoic acid and exerts biologic activity in mouse skin. J Invest Dermatol. 1996;107:714–719. DOI: 10.1111/1523-1747.ep12365603. PMID: 8875955.

[3] Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1:327–348. DOI: 10.2147/CIIA.2006.1.4.327.

[4] Creidi P, Vienne MP, Ochonisky S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39:960–965. DOI: 10.1016/S0190-9622(98)70270-1. PMID: 9843009.

[5] Pechère M, Pechère JC, Siegenthaler G, Germanier L, Saurat JH. Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology. 1999;199 Suppl 1:33–36. DOI: 10.1159/000051375. PMID: 10473957.

[6] Kwon HS, Lee JH, Kim GM, Bae JM. Efficacy and safety of retinaldehyde 0.1% and 0.05% creams used to treat photoaged skin: a randomized double-blind controlled trial. J Cosmet Dermatol. 2018;17:471–476. DOI: 10.1111/jocd.12551. PMID: 29663701.

[7] Kim J, Kim J, Lee YI, Suk J, Lee D, Lee JH. A pilot study evaluating the efficacy and safety of retinaldehyde-loaded niosomes against mild-to-moderate acne. J Cosmet Dermatol. 2021;20:3586–3592. DOI: 10.1111/jocd.14478. PMID: 34587353.

[8] Konisky H, Bowe WP, Yang P, Kobets K. The Clinical Efficacy and Tolerability of a Novel Retinaldehyde Serum with Firming Peptides to Improve Skin Texture and Signs of Photoaging. J Drugs Dermatol. 2024;23:992–997. DOI: 10.36849/JDD.8058R1. PMID: 39496127.

DOIs, PMIDs, and source links from the presentation are provided for verification.

PuriPharm Co. Ltd.

References

References / Formulation, scalp, and chemical identity

Reference numbers match the in-text citations. Original figure numbers and study conditions appear in the adjacent captions.

[9] Åkerström U, Gaudicheau C, Locret B, Gillbro JM. Efficacy and Safety of a Novel Anhydrous 0.1% Retinal-Based Concentrate with Hydrophilic Actives for Photoaged Skin: A Six-Week Prospective Study. Cosmetics. 2025;12:235. DOI: 10.3390/cosmetics12060235.

[10] Deda A, Odrzywołek W, Lebiedowska A, et al. Comparative Evaluation of Topical Stabilized Retinaldehyde 0.1% vs. 0.05% on Skin Biophysical and Biomechanical Parameters. Skin Res Technol. 2026;32:e70326. DOI: 10.1111/srt.70326. PMID: 41729119.

[11] Pisetpackdeekul P, Supmuang P, Pan-In P, et al. Proretinal nanoparticles: stability, release, efficacy, and irritation. Int J Nanomedicine. 2016;11:3277–3286. DOI: 10.2147/IJN.S111748. PMID: 27499622.

[12] Everts HB. Endogenous retinoids in the hair follicle and sebaceous gland. Biochim Biophys Acta. 2012;1821:222–229. DOI: 10.1016/j.bbalip.2011.08.017. PMID: 21914489.

[13] Wen L, Fan Z, Huang W, et al. Retinoic acid drives hair follicle stem cell activation via Wnt/β-catenin signalling in androgenetic alopecia. J Eur Acad Dermatol Venereol. 2025;39:189–201. DOI: 10.1111/jdv.20000. PMID: 38629345.

[14] Foitzik K, Spexard T, Nakamura M, Halsner U, Paus R. Towards dissecting the pathogenesis of retinoid-induced hair loss: all-trans retinoic acid induces premature hair follicle regression (catagen) by upregulation of TGF-β2 in the dermal papilla. J Invest Dermatol. 2005;124:1119–1126.

[15] Supmuang P, Wanichwecharungruang S. Triple protection delivery system for retinaldehyde: preparation, skin penetration and controlled release at the hair follicles. TechConnect Briefs. 2012;3:130–133. ISBN: 978-1-4665-6276-9.

[16] PubChem. Retinal, CID 638015. Molecular formula C₂₀H₂₈O; molecular weight 284.4 g/mol; official 2D chemical structure. https://pubchem.ncbi.nlm.nih.gov/compound/638015.

PuriPharm Co. Ltd. · service@puripharm.com · www.puriactives.com

DOIs, PMIDs, and source links from the presentation are provided for verification.

PuriPharm Co. Ltd.

Posted in News.